Sigma Planning Corp Has $508,000 Position in Cue Biopharma Inc (NASDAQ:CUE)

Sigma Planning Corp grew its holdings in Cue Biopharma Inc (NASDAQ:CUE) by 25.9% during the third quarter, Holdings Channel.com reports. The firm owned 60,210 shares of the company’s stock after acquiring an additional 12,405 shares during the period. Sigma Planning Corp’s holdings in Cue Biopharma were worth $508,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Russell Investments Group Ltd. bought a new position in shares of Cue Biopharma in the third quarter worth $67,000. Strs Ohio increased its holdings in shares of Cue Biopharma by 500.0% in the second quarter. Strs Ohio now owns 15,000 shares of the company’s stock worth $134,000 after purchasing an additional 12,500 shares during the period. Rock Creek Group LP bought a new position in shares of Cue Biopharma in the second quarter worth $447,000. Northern Trust Corp increased its holdings in shares of Cue Biopharma by 2.0% in the second quarter. Northern Trust Corp now owns 204,555 shares of the company’s stock worth $1,839,000 after purchasing an additional 3,970 shares during the period. Finally, Vanguard Group Inc. increased its holdings in shares of Cue Biopharma by 33.8% in the second quarter. Vanguard Group Inc. now owns 612,151 shares of the company’s stock worth $5,504,000 after purchasing an additional 154,639 shares during the period. 19.99% of the stock is currently owned by institutional investors.

Shares of Cue Biopharma stock traded up $0.32 during trading on Friday, hitting $8.84. The stock had a trading volume of 70,300 shares, compared to its average volume of 83,308. The company has a current ratio of 2.65, a quick ratio of 2.65 and a debt-to-equity ratio of 0.19. The business’s 50-day moving average is $8.09 and its 200 day moving average is $8.04. The firm has a market cap of $199.63 million, a price-to-earnings ratio of -4.56 and a beta of 1.21. Cue Biopharma Inc has a 12 month low of $4.16 and a 12 month high of $9.94.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Cue Biopharma (NASDAQ:CUE) last posted its earnings results on Thursday, August 8th. The company reported ($0.46) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.56) by $0.10. Cue Biopharma had a negative net margin of 2,039.41% and a negative return on equity of 151.93%. The company had revenue of $1.06 million during the quarter. As a group, equities analysts expect that Cue Biopharma Inc will post -1.96 EPS for the current year.

Several research analysts have recently weighed in on CUE shares. ValuEngine cut shares of Cue Biopharma from a “hold” rating to a “sell” rating in a report on Wednesday, October 30th. Robert W. Baird started coverage on shares of Cue Biopharma in a report on Thursday, July 25th. They issued an “outperform” rating and a $13.00 price target on the stock. Finally, Zacks Investment Research cut shares of Cue Biopharma from a “buy” rating to a “hold” rating in a report on Tuesday, October 8th.

About Cue Biopharma

Cue Biopharma, Inc, a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic designed to target and activate antigen-specific T cells for human papilloma virus driven cancers.

See Also: What is the quiet period?

Want to see what other hedge funds are holding CUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cue Biopharma Inc (NASDAQ:CUE).

Institutional Ownership by Quarter for Cue Biopharma (NASDAQ:CUE)

Leave a Reply

Your email address will not be published. Required fields are marked *

*